Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CI-994 in Advanced Myeloma
NCT00005624Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 1997
- Primary completion
- Feb 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacedinaline in multiple myeloma (MM), sponsored by Moffitt Cancer Center. Primary endpoint: Overall Response Rate at 5 years. Started Aug 1997; status: completed.
02
Drugs
tacedinaline
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00005624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005624.